Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Becanex PIEX is a standardized, plant-identical cannabis extract developed by Bedrocan Deutschland for use in pharmacy compounding. The product is manufactured using a specialized extraction process designed to preserve the complete profile of cannabinoids and terpenes found in the original cannabis flower, ensuring the final extract is chemically identical to the plant source. In the clinical setting, it is used by pharmacists to prepare individualized medications, such as oral drops or topical formulations, for patients requiring medical cannabis therapy. Its therapeutic effects are primarily mediated by the interaction of cannabinoids like THC and CBD with the endocannabinoid system, specifically targeting CB1 and CB2 receptors to manage symptoms such as chronic pain, spasticity, and nausea.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Becanex PIEX.